3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Conditions
Breast Neoplasms
103
Lymphoma
68
Lymphoma, Large B-Cell, Diffuse
49
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Sarcoma
33
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Leukemia
23
Burkitt Lymphoma
22
Neoplasms
19
Lymphoma, Mantle-Cell
18
Triple Negative Breast Neoplasms
15
Multiple Myeloma
15
Lymphoma, Follicular
15
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Anaplastic
12
Carcinoma, Hepatocellular
12
Breast Neoplasms, Male
11
Neuroblastoma
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Inflammatory Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, T-Cell
8
Osteosarcoma
7
Fallopian Tube Neoplasms
7
Urinary Bladder Neoplasms
6
Liposarcoma
6
Interventions
Paclitaxel
19
pembrolizumab
16
Carboplatin
12
Bevacizumab
8
lenvatinib
6
rucaparib
5
Nivolumab
5
Megestrol Acetate
5
Radiation
4
Indocyanine Green
4
Gemcitabine
4
Cisplatin
4
tisotumab vedotin
3
temsirolimus
3
Sirolimus
3
Sentinel Lymph Node Biopsy
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
olaparib
2
niraparib
2
ixabepilone
2
iso-sulfan blue
2
irosustat
2
epacadostat
2
durvalumab
2
copanlisib
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
Endometrial Neoplasms
×
Doxorubicin
×
Clear all
NCT03517449
2026-03-19
MK-3475-775
Eisai Inc.
Phase 3
Completed
827 enrolled
34 charts
1 FDA
NCT01767155
2018-07-31
ZoptEC
AEterna Zentaris
Phase 3
Completed
511 enrolled
16 charts
NCT00883116
2017-03-09
IXAMPLE2
R-Pharm
Phase 3
Terminated
551 enrolled
13 charts